For the Inventor, By the Inventor

Enter assignee name

New York, NY, United States of America

Imclone Systems, Inc.

USPTO Granted Patents = 22

% Expired Patents = 13.6

Trademarks = 3

Forward Citations = 530

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Neil I Goldstein (9 out of 13 patents)

Patricia Rockwell (7 out of 8 patents)

Jeffrey G Moore (5 out of 6 patents)

4. Charles T Tackney (4 out of 5 patents)

5. Maarten J Chrispeels (3 out of 5 patents)

6. Daniel J Hicklin (2 out of 3 patents)

7. M Gabriella Colucci (2 out of 2 patents)

8. Dale Lincoln Ludwig (1 out of 18 patents)

9. Jose William Saldanha (1 out of 49 patents)

10. Zhenping Zhu (1 out of 11 patents)

11. Steven Tarran Jones (1 out of 14 patents)

12. Peter Bohlen (1 out of 3 patents)

13. Dana M Fowlkes (1 out of 30 patents)

14. P Frederick Sparling (1 out of 8 patents)

15. Fang Liao (1 out of 1 patent)

22 patents: Sort by Forward Citations

1. 7498414 - Human antibodies specific to KDR and uses thereof (2009-03-03),

2. 7371574 - Antibody antagonists of VE-cadherin without adverse effects on vascular permeability (2008-05-13),

3. 7060808 - Humanized anti-EGF receptor monoclonal antibody (2006-06-13),

4. 6991794 - Progenitor cell preservation factors and methods for and products of their use (2006-01-31),

5. 6852321 - Lectin-derived progenitor cell preservation factor and methods of use (2005-02-08),

6. 6811779 - Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy (2004-11-02),

7. 6448077 - Chimeric and humanized monoclonal antibodies specific to VEGF receptors (2002-09-10),

8. 6410723 - VDUP1 promoter and methods of use thereof (2002-06-25),

9. 6365157 - Monoclonal antibodies specific to VEGF receptors and uses thereof (2002-04-02),

10. 6310195 - Nucleic acid encoding a lectin-derived progenitor cell preservation factor (2001-10-30),

11. 6280724 - Composition and method for preserving progenitor cells (2001-08-28),

12. 6086896 - Antigenic iron repressible protein from N. meningitidis related to the (2000-07-11),

13. 6084060 - Composition and method for preserving progenitor cells (2000-07-04),

14. 5955311 - Monoclonal antibodies specific to VEGF receptors and uses thereof (1999-09-21),

15. 5874542 - Single chain antibodies specific to VEGF receptors (1999-02-23),

Company Overview

ImClone Systems, Inc. is a biotechnology company based in New York, specializing in the development of innovative cancer therapies. The organization focuses on monoclonal antibodies and targeted therapies, aiming to improve treatment outcomes for patients with various types of cancer. With a commitment to advancing cancer care, ImClone engages in extensive research and development to bring new therapeutic options to market, contributing to the evolving landscape of oncology treatments.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

22 Patents

#376 in New York, NY

#892 in New York

#15,021 in US

#28,749 in the World

New York, NY, United States of America

Imclone Systems, Inc.

Forward Citations = 530

25 inventors:

Neil I Goldstein (9 out of 13 patents)

Patricia Rockwell (7 out of 8 patents)

Jeffrey G Moore (5 out of 6 patents)

4. Charles T Tackney (4 out of 5 patents)

5. Maarten J Chrispeels (3 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Imclone Systems, Inc.. Retrieved from https://idiyas.com/company/imclone-systems

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…